Bellevue-based longevity and preventative healthcare company Viome Life Sciences has secured $86.5 million in Series C funding. This substantial funding round brought the company’s total funding to $175 million.
Key investors, including Khosla Ventures, Bold Capital, and WRG Ventures, participated in this oversubscribed funding round. The funds will fuel ongoing research, development efforts, and an expanded retail footprint.
Viome Life Sciences combines Artificial Intelligence (AI) and proprietary RNA sequencing to analyze gene expression data from over 600,000 samples. This synergy results in personalized at-home tests and tailor-made health products.
These offerings include personalized supplement formulas, biotic blends for gut health, and even individualized oral biotic lozenges, all designed to enhance oral microbiome health.
Revolutionizing Gut Health
Viome’s groundbreaking Gut Intelligence Test is now available at more than 200 CVS locations and drugstore chains across the nation, both online and in-store.
This marks a significant milestone, as it is the first time such a comprehensive gut test is accessible in a national retail chain. The test scrutinizes vital indicators such as digestive efficiency, gut lining health, inflammatory activity, and more. The test results guide the provision of personalized recommendations for probiotic strains and prebiotic fibers.
Founder and CEO Naveen Jain underscores Viome’s commitment to addressing underlying health causes rather than merely alleviating symptoms. Viome Life Sciences empowers individuals to make informed decisions for healthier lives by amalgamating AI, RNA sequencing, and individual uniqueness. Jain views the recent funding and CVS expansion as strides toward their ambitious mission of impacting billions globally.
Tailored Nutrition Strategies
Viome Life Sciences challenges the notion of a universal healthy diet, recognizing the intricate symbiosis between human hosts and the diverse microbes within.
Each individual harbors a distinct microbiology, and Viome’s data-driven approach crafts personalized nutritional strategies and health solutions. Viome Life Sciences tailors recommendations to suit the individual’s biological makeup by leveraging AI and advanced algorithms.
The investment in Viome is more than financial; it symbolizes a commitment to transformative medical innovation. Industry experts, including Khosla Ventures’ Robbie Schwietzer, acknowledge Viome’s amalgamation of RNA technology and AI as a herald of a new era in healthcare.
Viome Life Sciences holds the potential to reshape healthcare paradigms and play a pivotal role in curbing chronic diseases across various health spectrums.
Scaling Impact
Since its establishment in 2016, Viome has remained steadfast in its pursuit of innovation and scientific excellence. The Series C funding round cements Viome’s leadership in science-backed, personalized health solutions.
The influx of funds propels Viome’s mission of translating scientific breakthroughs into tangible health solutions. Beyond extending longevity, Viome strives to redefine vitality, wellness, and health-conscious choices.
Viome Life Sciences’ pioneering approach, fortified by AI, RNA sequencing, and personalized nutrition, transforms preventive healthcare. As the company continues to revolutionize healthcare with data-driven, customized solutions, the potential to positively influence billions of lives remains steadfast at the heart of its resolute vision.
Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.
We Recomend:
- New York-based femtech startup Maven Clinic has secured $90 million in fresh funding
- Augmedics raises $82.5m in Series D funding for augmented reality surgical navigation platform
- Looxid Labs wins CES 2022 Innovation Award in Health and Wellness
- Preply’s AI-powered language learning platform raises $70M in Series C funding
- Data observability platform Acceldata secures $50 million in Series C
